Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
By lowering liver fat and indicators of liver scarring, retatrutide might stave off the progression of fatty liver disease, which is related to both cardiovascular and kidney health
GIP is the main incretin hormone in healthy people, causative of most the incretin effects but the insulin response after GIP secretion in T2DM is reduced [12]
Common dosing mistakes and how to avoid them The FDA does not issue safety alerts casually
The good news is that innovative drugs like semaglutide and Tirzepatide are changing the narrative by providing better treatment options for diabetes and obesity
As of now, research on small molecule GLP-1RAs is still mainly in the laboratory and early clinical trial stages